CN1654673A - Correlation between prostaglandin E receptor 2 gene and primary hypertension - Google Patents
Correlation between prostaglandin E receptor 2 gene and primary hypertension Download PDFInfo
- Publication number
- CN1654673A CN1654673A CN 200410016169 CN200410016169A CN1654673A CN 1654673 A CN1654673 A CN 1654673A CN 200410016169 CN200410016169 CN 200410016169 CN 200410016169 A CN200410016169 A CN 200410016169A CN 1654673 A CN1654673 A CN 1654673A
- Authority
- CN
- China
- Prior art keywords
- ptger2
- gene
- seq
- primer
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention discloses method of detecting primary hypertension susceptibility. The detection includes detecting individual prostaglandin E acceptor 2 gene PTGER2, transcript and/or protein, comparing with normal items to find the existing variation, which shows the greater attack probability of the individual in primary hypertension. The present invention also discloses the corresponding detection kit.
Description
Technical field
The present invention relates to molecular biology and medical field.Relate more specifically to the Prostaglin E Receptor 2 gene (Prostaglandin E Receptor 2, single nucleotide polymorphism PTGER2) (singlenucleotide polymorphism, SNP) and with the dependency of essential hypertension.The invention still further relates to the method and the test kit that detect these SNP.
Background technology
Hypertension is meant one group of clinical symptom grouping that systolic pressure or diastolic pressure raise.The rising of blood pressure and coronary heart disease, renal tubal dysfunction, hypertensive heart disease and the concurrent cerebral apoplexy of hypertension have an apparent causal connection.The up-to-date Case definition of hypertension is systolic pressure 〉=19kpa (140mmHg) or diastolic pressure 〉=12kpa (90mmHg), and meeting wherein, a person can be diagnosed as hypertension.
Most hyperpietic only has slight subjective symptoms in early days in elevation of blood pressure, as headache, dizziness, insomnia, tinnitus, fidgety, the difficult concentrated fatigue etc. that also occurs easily of working and learning energy.Along with the development of the state of an illness, when particularly developing complications, symptom increases and obviously gradually, as numbness of the fingers and stiff, lower limb pain appears when walking more, or the nervous sense of nape portion sore muscle appears.Show when, shortness of breath nervous, uncomfortable in chest, precordialgia that heart gets involved, frequent micturition at night, diuresis occur, show when urine is light that kidney is got involved, the kidney arteriole hardens when occurring.If obnubilation appears suddenly in the hyperpietic, breathe promptings such as dull irregular, gatism hematencephalon may take place, if engender a side limb activity inconvenience, numbness even benumb, should suspect the formation whether cerebral thrombosis is arranged.
The early stage Non Apparent Abnormality sign of hypertension occurs.When appearring in vitals such as brain, the heart, kidney, the mild damage can have unusual sign to occur.The performance of common heart abnormality has that apex beat moves to left, pareordia is praised the sample pulsatory feeling, auscultation apical region of heart first heart sound strengthens, second sound of aortic area strengthens and systolic murmur and diastolic murmur are arranged, show arteriosclerosis and left ventricular hypertrophy take place, if listen in the apical region of heart and the galloping horse sample rhythm of the heart may show the appearance of central force depletion.Also common in addition ear-lobe folding line, capillary pulsation, radial artery occur and pulsus durus or acrotism and lower limb intermittent claudication etc. occur.
In addition, because the development of some risk factor or hypertension itself can cause the remarkable or hurried rising of some hyperpietic's blood pressures, simultaneously with vitals functional lesions such as brain, the heart, kidney, retinas, a series of clinical special signs appear in serious threat to life, are called hypertensive emergency.The sickness rate of hypertensive emergency accounts for 5% of Hypertensive Population, and common have hypertensive encephalopathy, hematencephalon, acute left heart failure, the acute withdrawal syndrome of clonidine, Acute Myocardial Infarction, a radical type malignant hypertension etc.
About 5% left and right sides no conscious sympton among the hyperpietic does not know when blood pressure raises, and does not more know to have produced when the complication of blood vessel and organ injury yet, some patient even just know after cardiovascular accident has taken place and oneself suffer from hypertension.So, find out the genetic cause of hypertension incidence, hypertensive morbidity can be effectively controlled in preventing and detecting early, and disease is reduced to minimum to the injury of human body.
(essential hypertension EH) also is essential hypertension to essential hypertension, is a kind of independently disease, and the cause of disease of oneself, rule and the clinical manifestation that the generation development lapses to are arranged.Mainly show as the rising of arteriotony clinically.Account for more than 90% of crowd hyperpietic, at present pathogeny is not clear fully as yet, mainly just can be diagnosed as essential hypertension (essential hypertension) after having got rid of the hypertension that other diseases causes.The rising of arteriotony mainly is because of due to periphery arteriole resistance increases, and in various degree Q volume of blood and kinemic increase are arranged simultaneously.Often cause late period internal organs such as the heart, brain, kidney to be got involved severe complications such as hypertensive heart disease, heart failure, renal tubal dysfunction, hematencephalon take place.The treatment of essential hypertension mainly is to bring high blood pressure down to prevent the generation of complication simultaneously.The primary hypertension patient cause of death is cerebrovascular accident, cardiovascular accident and renal insufficiency, and for seeing, in heart failure and uremia is taken second place more with cerebrovascular accident in China, and American-European countries sees with heart failure more, and cerebrovascular accident and uremia are taken second place.
Essential hypertension is as modal cardiovascular disorder, and its sickness rate rises year by year, and can cause the serious heart, brain, kidney complication, is the primary hazard factor of cerebral apoplexy and coronary heart disease.EH is a kind ofly interacted and the polygenic disease of morbidity by inherited genetic factors and environmental factors, and the genetic mechanism of seeking the EH genes involved and then illustrating hypertension incidence has become the focus of present research.
Though have many researchs about range gene polymorphism and essential hypertension, do not confirm the report of PTGER2 gene and essential hypertension dependency, more do not confirm the SNP of PTGER2 gene and the report of essential hypertension dependency.
In sum, for the final treatment hypertension that realizes, this area presses for seeks the essential hypertension tumor susceptibility gene, and develops method, test kit that detects essential hypertension and relevant medicine.
Summary of the invention
Purpose of the present invention just provides a kind of diagnosis (especially early diagnosis) hypertensive method and detection kit.
Another object of the present invention provides the hypertensive method of a kind of new treatment.
A further object of the present invention provides the hypertensive pharmaceutical composition of a kind of treatment.
In a first aspect of the present invention, a kind of method that the hypertension susceptibility of individuality is diagnosed is provided, it comprises step:
Detect this individual PTGER2 gene, transcript and/or albumen, and compare with normal PTGER2 gene, transcript and/or albumen,
There are differences and just show that this individuality suffers from hypertensive possibility and be higher than normal population.
In another preference, what detect in the described method is gene or the transcript of PTGER2, and with normal PTGER2 nucleotide sequence comparing difference.
In another preference, described difference is following single nucleotide polymorphism:
1391 G → A;
Wherein, the nucleotide position numbering is based on SEQ ID NO:1.
In a second aspect of the present invention, provide a kind of test sample whether to have the method for the single nucleotide polymorphism of Prostaglin E Receptor 2 gene PTGER2, comprise step:
(a) with the PTGER2 gene of PTGER2 gene-specific primer amplification sample, obtain amplified production; With
(b) detect whether there is following single nucleotide polymorphism in the amplified production:
1391 G → A;
Wherein, the nucleotide position numbering is based on SEQ ID NO:1.
In another preference, described gene-specific primer has the sequence of SEQ ID NO:2 and 3.
In another preference, the length of described amplified production is 100-3000bp, and contains among the SEQID NO:1 the 1391st.
In a third aspect of the present invention, provide a kind of detection hypertensive test kit, it comprises the primer of specific amplification PTGER2 gene or transcript, more preferably, it is 100-3000bp that described primer amplification goes out length, and contains among the SEQ ID NO:1 the 1391st amplified production.
In another preference, described test kit also contains the reagent that is selected from down group:
(a) with SEQ ID NO:1 in the 1391st sudden change bonded probe;
(b) the 1391st sudden change restriction enzyme among the identification SEQ ID NO:1.
In another preference, described sudden change is selected from following single nucleotide polymorphism:
1391 G → A;
Wherein, the nucleotide position numbering is based on SEQ ID NO:1.
In a fourth aspect of the present invention, a kind of pharmaceutical composition is provided, it contains the PTGER2 albumen and the pharmaceutically acceptable carrier of safe and effective amount.
Embodiment
The inventor is through deeply and extensive studies, and the SNP of a large amount of candidate genes is measured and analyzes.Find first and proved that PTGER2 gene and hypertension are closely related, and found its new function: the change of PTGER2 will cause hypertension, wherein the association study result shows, (1391 G → A) there is significant difference (P＜0.05) in the distribution in case and control group, therefore can be used as to detect hypertensive specificity SNP at the SNP of the 1391st of PTGER2.Finished the present invention on this basis.
The PTGER2 gene
Prostaglin E Receptor 2 gene (Prostaglandin E Receptor 2, PTGER2) detailed sequence can be the nucleotide sequence (can referring to network address http://www.ncbi.nlm.nih.gov/) of AF134201 referring to accession number, shown in SEQ ID NO:1.
Prostaglandin(PG) is to be present in the active substance with multiple physiological action that the class unsaturated fatty acids in animal and human's body is formed.Find the earliest to be present in people's the seminal fluid, thought at that time that this material was discharged by prostate gland, thereby name and be prostaglandin(PG).Now proved prostaglandin(PG) in the seminal fluid mainly from seminal vesicle, the many histocytes of the whole body that removes can both produce prostaglandin(PG).The chemical nature of prostaglandin(PG) is by a five-ring and two 20 carbon unsaturated fatty acidss that side chain constitutes.By its structure, prostaglandin(PG) is divided into types such as A, B, C, D, E, F, G, H, I.The transformation period of prostaglandin(PG) is extremely lacked (1～2 minute), except that prostacyclin I2, other prostaglandin(PG) is degraded rapidly through lung and liver, so prostaglandin(PG) is unlike typical hormone, activity by the remote target tissue of circulating effect, but produce and release in the part, bring into play regulating effect to the cell of generation prostaglandin(PG) itself or to the physiological activity of adjacent cells.Prostaglandin(PG) to internal secretion, reproduction, digestion, blood breathe, cardiovascular, uropoiesis and neural system all have effect.Intensive shrinks because prostaglandin(PG) can cause the uterus frequency, so be applied to the aspects such as induced labor, artificial abortion and contraception of full-term pregnancy, has obtained certain effect.The application of aspects such as prostaglandin(PG) treatment asthma, gastroenteritic ulcer disease, shock, hypertension and cardiovascular disorder is also among research.
PGE can reduce thromboxane A2 and generate; effectively suppress the effect that hematoblastic aggegation and atheroma lipid patch form, can also expand peripheral blood vessel and coronary vasodilator, reduce Peripheral resistance and blood pressure; the protection ischemic myocardial is arranged, dwindle myocardial infarction area etc.Clinically, prostaglandin E1 has been used to treat early high blood pressure, diseases such as II phase hypertension.
As the acceptor of PGE, PTGER2 plays a part the regulation domain blood flow in arteries.Find that from animal model test the mouse of PTGER2 mutant shows the mouse (Tiller et al.J.Clin.Invest.103:1539-1545,1999) that systolic pressure obviously will be lower than wild-type owing to lack PTGER2.And when the mouse of this class mutant was raised food with high salt, their blood pressure had significantly raise.This result has illustrated that also gene PTGER2 plays an important role in the ionic regulation and control receiving of kidney.
The inventor checks order to the almost whole zone in the PTGER2 gene, many SNP have been found, wherein most of SNP and hypertension susceptibility are also uncorrelated, yet association study shows 1391 G → A but are and the very high SNP of hypertension susceptibility cognation.This SNP is positioned at the promoter region of PTGER2, points out influentially to the transcriptional level of PTGER2, and then causes influencing the interaction of PGE and acceptor, and the hypertension susceptibility that finally causes the carrier is apparently higher than normal population.
Based on new discovery of the present invention, PTGER2 albumen or polypeptide have many-sided new purposes.These purposes include, but is not limited to: the direct disease (as hypertension) due to the low or forfeiture and be used to screen the material that promotes the PTGER2 protein function as pharmacological agent PTGER2 protein function, and as antibody, polypeptide or other part.The peptide molecule that can stimulate people PTGER2 protein function that can be used for seeking therapeutic value with the recombinant human PTGER2 protein screening peptide library of expressing.
On the other hand, the present invention also comprises people PTGER2 DNA or the polypeptide of its fragment coding has specific polyclonal antibody and monoclonal antibody, especially monoclonal antibody.Here, " specificity " is meant that antibody capable is incorporated into people PTGER2 gene product or fragment.Preferably, refer to that those can combine with people PTGER2 gene product or fragment but nonrecognition and be incorporated into the antibody of other irrelevant antigen molecule.Among the present invention antibody comprise those can in conjunction with and suppress the proteic molecule of people PTGER2, comprise that also those do not influence the antibody of people PTGER2 protein function.
The present invention not only comprises complete mono-clonal or polyclonal antibody, but also comprises having immunocompetent antibody fragment, as Fab ' or (Fab)
2Fragment; Heavy chain of antibody; Light chain of antibody; Genetically engineered strand Fv molecule; Or chimeric antibody.
Antibody of the present invention can be prepared by the known various technology of those skilled in that art.For example, the people PTGER2 gene product of purifying or its have antigenic fragment, can be applied to animal to induce the generation of polyclonal antibody.Similarly, expressing human PTGER2 albumen or its have antigenic segmental cell and can be used to immune animal and produce antibody.Multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.
Antibody of the present invention also can be monoclonal antibody.This type of monoclonal antibody can utilize hybridoma technology to prepare.Antibody of the present invention comprises the antibody that can block people PTGER2 protein function and the antibody that does not influence people PTGER2 protein function.Each antibody-like of the present invention can utilize the fragment or the functional zone of people PTGER2 gene product, obtains by the routine immunization technology.These fragments or functional zone can utilize recombinant methods or utilize Peptide synthesizer synthetic.Can come immune animal and produce with the gene product of producing in the prokaryotic cell prokaryocyte (for example E.Coli) with the unmodified form bonded antibody of people PTGER2 gene product; With posttranslational modification form bonded antibody (as the albumen or the polypeptide of glycosylation or phosphorylation), can come immune animal and obtain with the gene product that produces in the eukaryotic cell (for example yeast or insect cell).
The proteic antibody of anti-people PTGER2 can be used in the immunohistochemistry technology, detect people PTGER2 in the biopsy specimen proteic what and/or whether suddenly change.A kind of preferred anti-PTGER2 antibody is the antibody of the normal PTGER2 of nonrecognition PTGER2 but identification suddenlys change, perhaps discerns normal PTGER2 but the antibody of nonrecognition sudden change PTGER2.Utilize these antibody, the hypertension susceptibility that can carry out protein level easily detects.
Utilize PTGER2 albumen of the present invention,, can filter out with PTGER2 albumen interactional material takes place, as inhibitor, agonist or antagonist etc. by various conventional screening methods.
PTGER2 albumen of the present invention and antibody thereof, inhibitor, agonist, antagonist etc. when using (administration) in treatment, can provide different effects.Usually, can these materials are formulated in nontoxic, inert and the pharmaceutically acceptable aqueous carrier medium, wherein pH is about 5-8 usually, and preferably pH is about 6-8, although the pH value can be with being changed to some extent by preparation Substance Properties and illness to be treated.The pharmaceutical composition for preparing can carry out administration by conventional route, comprising (but being not limited to): intramuscular, intravenously or subcutaneous administration.
Normal PTGER2 polypeptide can be directly used in disease treatment, for example, is used for hypertension therapeutic.When using PTGER2 albumen of the present invention, also can use the hypertensive medicament of other treatment simultaneously.
The present invention also provides a kind of pharmaceutical composition, and it contains PTGER2 albumen of the present invention and the pharmaceutically acceptable carrier or the vehicle of safe and effective amount.This class carrier comprises (but being not limited to): salt solution, damping fluid, glucose, water, glycerine, ethanol and combination thereof.Pharmaceutical preparation should be complementary with administering mode.Pharmaceutical composition of the present invention can be made into the injection form, for example is prepared by ordinary method with the physiological saline or the aqueous solution that contains glucose and other assistant agents.Pharmaceutical composition such as tablet and capsule can be prepared by ordinary method.Pharmaceutical composition such as injection, solution, tablet and capsule should be made under aseptic condition.The dosage of activeconstituents is the treatment significant quantity, for example every day about 0.1 microgram/kg body weight-Yue 10 mg/kg body weight.In addition, polypeptide of the present invention also can use with the other treatment agent.
When making pharmaceutical composition, be that the PTGER2 albumen of safe and effective amount or its antagonist, agonist are applied to Mammals, wherein this safe and effective amount is usually at least about 0.1 microgram/kg body weight, and in most of the cases be no more than about 10 mg/kg body weight, preferably this dosage is about 0.1 microgram/kg body weight-Yue 100 micrograms/kg body weight.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.
The proteic polynucleotide of people PTGER2 also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to the proteic expression of PTGER2 of the proteic nothing expression of PTGER2 or unusual/non-activity.The method that structure carries the recombinant viral vector of PTGER2 gene is found in existing document (Sambrook, et al.).Recombinant human PTGER2 gene can be packaged in the liposome in addition, and then is transferred in the cell.
Polynucleotide imports tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.
The invention still further relates to the diagnostic testing process of quantitative and detection and localization people PTGER2 protein level.These tests are known in the art, for example ELISA etc.
Whether having the proteic method of PTGER2 in a kind of detection test sample is to utilize the proteic specific antibody of PTGER2 to detect, and it comprises: sample is contacted with the PTGER2 protein specific antibody; Observe whether form antibody complex, formed antibody complex and just represented to exist in the sample PTGER2 albumen.
The proteic polynucleotide of PTGER2 can be used for the diagnosis and the treatment of PTGER2 protein related diseases.Aspect diagnosis, the proteic polynucleotide of PTGER2 can be used for detecting the proteic expression of PTGER2 PTGER2 abnormal exprssion whether or under morbid state.Can be used for the hybridization of biopsy specimen to judge the proteic abnormal expression of PTGER2 as the PTGER2 dna sequence dna.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out RNA-polymerase chain reaction (RT-PCR) amplification in vitro with the special primer of PTGER2 albumen and also can detect the proteic transcription product of PTGER2.
The sudden change that detects the PTGER2 gene also can be used for diagnosing hypertension.Detection can be at eDNA, also can be at genomic dna.The form of PTGER2 protein mutation comprises that the point mutation compared with normal wild type PTGER2 dna sequence dna, transposition, disappearance, reorganization and other are any unusual etc.It is the SNP shown in the table 2 that one class is preferably suddenlyd change.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.
The method of the detection SNP of the present invention of most convenient is by the PTGER2 gene with PTGER2 gene-specific primer amplification sample, obtains amplified production; Detect then and whether have following single nucleotide polymorphism in the amplified production: 1391 G → A, wherein, nucleotide position is numbered based on SEQ ID NO:1.
Should understand, after the present invention has disclosed the SNP and hypertensive dependency of PTGER2 gene first, but those skilled in the art can design the amplified production that specific amplification goes out to contain this SNP position easily, determine whether to exist 1391 G → A by methods such as order-checkings then.Usually, the length of primer is 15-50bp, preferably is 20-30bp.Though the complete complementation of primer and template sequence is preferred, one skilled in the art will appreciate that at primer and template to have under the situation of certain not complementary (especially 5 ' of primer end) also can increase specifically (promptly only amplifying required fragment).The method that contains the test kit of these primers and use these primers is all within the scope of the invention, as long as the amplified production that this primer amplification goes out contains the correspondence position of SNP of the present invention.A kind of preferred primer is to having the sequence of SEQ IDNO:2 and 3.
Though the length of amplified production is not particularly limited, the length of amplified production is 100-3000bp usually, preferably is 150-2000bp, more preferably is 200-1000bp.These amplified productions all should contain among the SEQ ID NO:1 the 1391st.
Because SNP of the present invention and hypertension have very high cognation, therefore not only can be used in early days diagnosing primary hypertension more exactly, and can make the carrier just take reasonable precautions (as on diet, taking corresponding control) against a rainy day at premorbid not, thereby improve carrier's lifetime and life quality, therefore have earth shaking using value and social benefit.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold Spring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.
Embodiment 1
1.1 research object
Because blood pressure is the quantitative character that is subjected to multiple such environmental effects that polygene participates in, the inevitable problem that when analyzing genes involved, will consider genetic heterogeneity.Select the relatively single isolated crowd of genetic background will help to reduce the influence of genetic heterogeneity, simultaneously because these colonies have comparison fixed living environment and more consistent living habit make Effect of Environmental reduce greatly as the material of research multigenic disease.Select such colony,, still therefrom choose family and carry out pedigree analysis, all help to improve the detection sensitivity in hypertension susceptible gene site no matter be to be used for the linkage disequilibrium analysis.Therefore selected in the present embodiment isolated population is as research object (isolated population has the relative uniformity of genetic background, the advantage that founder's number is fewer).
On the basis of informed consent random collecting 324 ages at the Han nationality's individuality more than 50 years old, all come from Dabie Mountain, Yuexi County, Anhui Province and ring the intestines town.80% individuality has only 6 surnames, and founder's number should be fewer, and other individuality of identity comes from same founder.The hypertension sample of selecting for use requires systolic pressure to be not less than 140mmHg, and diastolic pressure is not less than 90mmHg, measures blood pressure and averages for twice.
Select 11% being positioned at the top that blood pressure distributes (37 examples are individual wherein; SBP＞178mmHg) and 7% (22 individualities that are positioned at the lowermost end that blood pressure distributes are arranged; SBP＜104mmHg) is totally 59 individualities, carries out the detection of SNP by the method for direct order-checking.
1.2 experimental technique and result
1.2.1 DNA extraction
Extract DNA with conventional phenol chloroform method from people's blood, concentration correction is used for conventional pcr amplification to 20ng/ul.
1.2.2 the design of PCR and sequencing primer
According to the genome sequence of PTGER2 among the GenBank, design and synthetic following primer.Concrete primer is as shown in table 1 below.
Table 1 primer sequence table
| The primer title | Sequence (5 '-3 ') | SEQ?ID?NO： |
| Adopted primer is arranged | GGAATCCATGCCATGAGAAG | ????2 |
| Antisense primer | ATCCAGTTTGGCAGACAACA | ????3 |
1.2.3 the pcr amplification of PTGER2 gene
DNA with extraction is a template, uses the Taq enzyme, carries out pcr amplification with the Touchdown program on GeneAmp 9700 PCR instrument.Reaction conditions is: 94 ℃ of pre-sex change 2 minutes, and 94 ℃ of sex change 30 seconds, 63 ℃ of annealing 40 seconds, 72 ℃ were extended totally 10 circulations, 0.5 ℃ of each cycle annealing lapse of temperature 40 seconds; Later 94 ℃ of sex change 30 seconds were annealed 40 seconds for 58 ℃, and 72 ℃ were extended totally 30 circulations 40 seconds; Last 72 ℃ were extended 7 minutes.Pcr amplification product is verified through agarose gel electrophoresis.
As a result, obtain the amplified production of 368bp.
1.2.4 the discovery of SNP and detection
The PCR product is used ABI-PRISM behind the Resin resin purification
TM377 dna sequencing instrument (appliedbiosystems of u.s.a. applied biosystem company (ABI)) carry out the two-way order-checking of the terminal cessation method of fluorescent mark, and the interpretation and the SNP that carry out sequence with Polyphred software (the http://droog.mbt.washington.edu/Polyphred.html of Washington, DC university) confirm.
As a result, find to exist following SNP:1391 position G → A.
1.2.5 SNP gene type and association analysis
Carry out the SNP gene type with direct unidirectional sequencing.Promptly in hypertensive patient and normal arterial pressure control group, carry out somatotype and association analysis.
Carry out chi square test after allelic frequency statistics is come out,, determine whether that tentatively allelic frequency and blood pressure level are chain by blood pressure the highest 11% and 7% minimum individual data items are compared.
The frequency of G type SNP in the hypertension individuality that found that among the SEQ ID NO:1 1391 is 16%, and the frequency in the ypotension crowd is 27.6%.Difference on the frequency between the two is 11.5%, has confirmed among the SEQ ID NO:1 1391 G/A type SNP and the hypertensive dependency that exists.
Embodiment 2
Essential hypertension susceptibility detection kit
As described in embodiment 1, sudden change and the high blood pressure disease of 1391 G → A are closely related among the SEQ ID NO:1.Therefore, can be that template increases and detects at DNA based on this sudden change design PTGER2 gene-specific primer with patient.
Prepare a test kit (100 person-times), it contains:
| Title | Sequence | Concentration |
| Adopted primer is arranged | SEQ?ID?NO：2 | 100pmol |
| Antisense primer | SEQ?ID?NO：3 | 100pmol |
| The PCR reaction solution | Contain Taq enzyme dNTP magnesium ion PCR reaction buffer | |
Extract male sex's patients'blood 3ml to be detected, use ordinary method (or using specific test kit) from blood, to extract DNA.PCR primer in the hypertension detection kit is diluted to 1 ì mol/ ì l, is that template is carried out the PCR reaction with the primer that is provided with the DNA that is extracted.Behind the PCR product purification, use ABI-PRISM
TM377 dna sequencing instrument carry out the two-way order-checking of the terminal cessation method of fluorescent mark, and the interpretation and the SNP that carry out sequence with Polyphred software confirm.
Perhaps, amplified production and normal control are carried out stratographic analysis with sex change high performance liquid chromatograph (DHPLC), also can detect 1391 G → A.
Detected result, the hypertension susceptibility that contains the detected object of 1391 G → A is higher than normal population.
All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Sequence table
＜110〉Fudan University
Research Center of Shanghai Human Genome
＜120〉dependency of Prostaglin E Receptor 2 gene and essential hypertension
<130>040150
<160>3
<170>PatentIn?version?3.1
<210>1
<211>3875
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>1
ctatgtaaac?tgaaactgta?tcaaaatgct?gacactaaaa?ttagaaatgg?gaagaagtag????60
tttttaaacc?acaaaattaa?ctgggggtaa?ctgacaagca?agattagact?gcacttaaag????120
gaacaaacgt?gatggtccag?ttgtaacgta?gggacagcaa?acttatcaac?tttcctattc????180
agcaatatag?caacagggaa?cacagcaaat?gttaacccaa?cacacacaca?cacacacaca????240
cacacacaca?cattgtatgt?attctgtcca?aatgctggaa?gcaattaaaa?ggagtaattt????300
gaacaagcaa?tgctgagcag?cacagtaatt?aataggatac?tggcctccca?agatttatag????360
ggcccactct?agtcttcctc?ttgtcacata?ccttaccaca?ggtgagacac?cctcagggca????420
ctattcaccc?agaccccatt?acccctccat?tctagaccac?cttccaggta?cctgagatca????480
tgaaatttcc?tgctcaaatg?ttggtcccat?aactcgcttc?cagggcttga?tcaggcatct????540
tccctaggtc?catccaatca?agggtcattt?gcatgtttga?gatgcatatt?cccaggacca????600
aggtggcttt?ggggagagag?cttggttatc?aacaactata?gtgtccacat?attgaactat????660
actgtccaca?tattgaacta?tactctccac?atatttctgt?gcaagactcc?ttgtggtgca????720
agactgagtc?aggggttagg?aagacaaggg?ggcaggggcc?tgggggagga?tcttcaactg????780
cactcttgct?ctcgtattca?caaaaaccag?gggccggcct?gccaccaggt?acccatccaa????840
agaaaagcta?gagacaaata?tataggaaag?gttaaatagt?aggtttttgt?tgtgaggggc????900
cttatgaaaa?ttaaaaaggt?ataaaaatat?ttggaaaata?agcactgtgc?aaattcagtg????960
aatctaaaat?cccttattta?atagtaaaac?tgcagtgcag?aattatgcta?taaatcatag????1020
tgttttccta?ttaagaaata?cttctgattt?aagtttgatg?tttccccatt?gcttggggtg????1080
agatggggga?atgttggagt?aggggaatag?tcagagatgg?atggcaaaga?ttggtaataa????1140
gttgttactg?acctgcagag?tttacagctt?gaaagaaaaa?ctgtaggagt?taagatcctc????1200
tttcctagga?atccatgcca?tgagaagttt?agggattgaa?gtagtgcctg?ctgacatgtg????1260
aaaaccggcc?tgtaaacttt?gcaagcgatc?cagtaaatta?tgcttgttct?agtgggaacc????1320
cccccacccc?aactccgcat?tccaatcccc?aggccagaat?catcaaagtt?ggcaaaaaat????1380
attcatggag?ggtaagcagg?ctgtagcaag?ataggctctt?cagcaggcaa?tctttgcttc????1440
ctcccacgtt?atgactgtct?ttcttgccag?ttccctaggc?agatcagacc?cttcacttcc????1500
cagttggcct?cccttcccca?agtgaatgtg?acttcttaca?gaacacaatt?acctatgttg????1560
tctgccaaac?tggattttgt?tttgttttgt?tttgtgttaa?atatcagccc?attttcacga????1620
ctctgcaatt?atgacaatat?gtggtaggaa?accattactg?tcagctccag?tctgaaactg????1680
gccacttacc?aatacacttt?gccaggaaca?agtctttctg?gatggatact?acgtggttaa????1740
caacatgtaa?agataacggc?taaacaaaat?atcaacattt?tcttacaagg?ctcagcttaa????1800
ggacagaaca?gtgatgtgca?atggttttca?tgttgtatcc?acaaacacaa?ttctgtataa????1860
gaaacactcc?tcttttttta?atggttgctt?aaacaagtgg?ttatccgtta?tgctgttgac????1920
ataggaaacg?gtgaaatgct?agtaaccgaa?tcaaagcggc?agtgcaacag?gccgctcggt????1980
ggtgcgcatt?gtgtggtttg?gttccttgga?tggacacact?tgctttacgc?ttcatcccaa????2040
tttttgtccc?aacctcttag?tgtatcttcc?tgggaatagt?aaaaacaaag?caaaacattc????2100
tggtcttact?tcaagctgcc?tttgcactgt?tattcccttg?ttccgctcat?ttcacgggat????2160
tgggttctcc?taacttcatt?gtttggtgag?ttgctttgct?ttgctcgttg?ccccgatctt????2220
ctgtgtattc?tgcgcagacc?ccgcaagtgg?tcctgcactc?cctcccagcc?ctctgctggg????2280
gcttaacgct?tcccagccga?ggtcagactg?ccgtgcgctt?cgagtaccgg?accccgagga????2340
agcgagaaac?gccgctcccg?ccggtcgcgg?gcagcttcag?tacaccggca?acacgcgcgc????2400
ctctgcccag?tgccgcgccc?agcgggtgct?cagactcctt?ctctccctcc?ccgccggcgc????2460
accccaggga?ctcggaacgc?ccccgcgagt?gtgacgcgtc?ctgcctcccc?tgcagctcgc????2520
ggacactcgc?acttgcaagg?cctggccagc?actcttgggc?ccgccccccg?acagtgcggg????2580
ggcggagacg?acggctcccc?taggctctgg?ctcccggcct?tggccggcgc?gggtaggcgc????2640
gggagcctcg?agcgccgctc?ggatgcagca?gccgagccgc?cactcggcgc?gcggcgggaa????2700
acccagggca?agccgccgtc?ggcgcgctgg?gtgcgggaag?ggggctctgg?atttcggtcc????2760
ctcccctttt?tcctctgagt?ctcggaacgc?tccagctctc?agaccctctt?cctcccaggt????2820
aaaggccggg?agaggagggc?gcatctcttt?tccaggcacc?ccaccatggg?caatgcctcc????2880
aatgactccc?agtctgagga?ctgcgagacg?cgacagtggc?ttcccccagg?cgaaagccca????2940
gccatcagct?ccgtcatgtt?ctcggccggg?gtgctgggga?acctcatagc?actggcgctg????3000
ctggcgcgcc?gctggcgggg?ggacgtgggg?tgcagcgccg?gccgcaggag?ctccctctcc????3060
ttgttccacg?tgctggtgac?cgagctggtg?ttcaccgacc?tgctcgggac?ctgcctcatc????3120
agcccagtgg?tactggcttc?gtacgcgcgg?aaccagaccc?tggtggcact?ggcgcccgag????3180
agccgcgcgt?gcacctactt?cgctttcgcc?atgaccttct?tcagcctggc?cacgatgctc????3240
atgctcttcg?ccatggccct?ggagcgctac?ctctcgatcg?ggcaccccta?cttctaccag????3300
cgccgcgtct?cggcctccgg?gggcctggcc?gtgctgcctg?tcatctatgc?agtctccctg????3360
ctcttctgct?cgctgccgct?gctggactat?gggcagtacg?tccagtactg?ccccgggacc????3420
tggtgcttca?tccggcacgg?gcggaccgct?tacctgcagc?tgtacgccac?cctgctgctg????3480
cttctcattg?tctcggtgct?cgcctgcaac?ttcagtgtca?ttctcaacct?catccgcatg????3540
caccgccgaa?gccggagaag?ccgctgcgga?ccttccctgg?gcagtggccg?gggcggcccc????3600
ggggcccgca?ggagagggga?aagggtgtcc?atggcggagg?agacggacca?cctcattctc????3660
ctggctatca?tgaccatcac?cttcgccgtc?tgctccttgc?ctttcacggt?aagtcactcc????3720
ctacgtttcc?acagcccggc?tctgctcagc?cttctcatgc?tctcccctga?cgcctccacc????3780
ctttccaccg?ccctacaaac?tttttgcaac?ttgtaaaaat?atgtcctaat?ttgtaaagat????3840
ctgtagcctt?ccccactagt?ttcccctcct?cttta???????????????????????????????3875
<210>2
<211>20
<212>DNA
＜213〉artificial sequence
<220>
<221>misc_feature
＜223〉primer
<400>2
ggaatccatg?ccatgagaag??????????????????????????????????????????????????20
<210>3
<211>20
<212>DNA
＜213〉artificial sequence
<220>
<221>misc_feature
＜223〉primer
<400>3
atccagtttg?gcagacaaca??????????????????????????????????????????????????20
Claims (10)
1. whether a vitro detection sample exists the method for the single nucleotide polymorphism of Prostaglin E Receptor 2 gene PTGER2, it is characterized in that, comprises step:
(a) with the PTGER2 gene of PTGER2 gene-specific primer amplification sample, obtain amplified production; With
(b) detect whether there is following single nucleotide polymorphism in the amplified production:
1391 G → A;
Wherein, the nucleotide position numbering is based on SEQ ID NO:1.
2. the method for claim 1 is characterized in that, described gene-specific primer has the sequence of SEQ ID NO:2 and 3.
3. the method for claim 1 is characterized in that, the length of described amplified production is 100-3000bp, and contains among the SEQ ID NO:1 the 1391st.
4. one kind is detected hypertensive test kit, it is characterized in that it comprises the primer of specific amplification PTGER2 gene or transcript, and it is 100-3000bp that described primer amplification goes out length, and contains among the SEQID NO:1 the 1391st amplified production.
5. test kit as claimed in claim 4 is characterized in that, it also contains the reagent that is selected from down group:
(a) with SEQ ID NO:1 in the 1391st sudden change bonded probe;
(b) the 1391st sudden change restriction enzyme among the identification SEQ ID NO:1.
6. test kit as claimed in claim 5 is characterized in that, described sudden change is following single nucleotide polymorphism:
1391 G → A;
Wherein, the nucleotide position numbering is based on SEQ ID NO:1.
7. test kit as claimed in claim 4 is characterized in that described primer has the sequence of SEQ IDNO:2 and 3.
8. method that the hypertension susceptibility of individuality is diagnosed is characterized in that it comprises step:
Detect this individual PTGER2 gene, transcript and/or albumen, and compare with normal PTGER2 gene, transcript and/or albumen,
There are differences and just show that this individuality suffers from hypertensive possibility and be higher than normal population.
9. method as claimed in claim 8 is characterized in that, detection be gene or the transcript of PTGER2, and with normal PTGER2 nucleotide sequence comparing difference.
10. method as claimed in claim 9 is characterized in that, described difference is following single nucleotide polymorphism:
1391 G → A;
Wherein, the nucleotide position numbering is based on SEQ ID NO:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410016169 CN1654673A (en) | 2004-02-09 | 2004-02-09 | Correlation between prostaglandin E receptor 2 gene and primary hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410016169 CN1654673A (en) | 2004-02-09 | 2004-02-09 | Correlation between prostaglandin E receptor 2 gene and primary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1654673A true CN1654673A (en) | 2005-08-17 |
Family
ID=34892181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410016169 Pending CN1654673A (en) | 2004-02-09 | 2004-02-09 | Correlation between prostaglandin E receptor 2 gene and primary hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1654673A (en) |
-
2004
- 2004-02-09 CN CN 200410016169 patent/CN1654673A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1654673A (en) | Correlation between prostaglandin E receptor 2 gene and primary hypertension | |
| CN1654672A (en) | Correlation between prostaglandin E receptor 2 gene and primary hypertension | |
| CN1654679A (en) | Correlation between prostaglandin E receptor 2 gene and primary hypertension | |
| CN1654680A (en) | Correlation between prostaglandin E receptor 2 gene and primary hypertension | |
| CN1654674A (en) | Correlation between prostaglandin E receptor 2 gene and primary hypertension | |
| CN1654675A (en) | Correlation between prostaglandin E receptor 2 gene and primary hypertension | |
| CN1654678A (en) | Correlation between prostaglandin E receptor 2 gene and primary hypertension | |
| CN1661084A (en) | Relativity between transfer protein gene of cholesterol ester and essential hypertension | |
| CN1661085A (en) | Relativity between gene of transfer protein of cholesterol ester and essential hypertension | |
| CN1661072A (en) | Relativity between gene 1A of arginine-vasopressin receptor and essential hypertension | |
| CN1661071A (en) | Relativity between C2 gene of apolipoprotein and essential hypertension | |
| CN1661056A (en) | Relativity between gene of haptoglobin and essential hypertension | |
| CN1661065A (en) | Relativity between SNP gene of insulin receptor and essential hypertension | |
| CN1661063A (en) | Relativity between gene of haptoglobin and essential hypertension | |
| CN1661064A (en) | Relativity between gene of haptoglobin and essential hypertension | |
| CN1661057A (en) | Relativity between gene of haptoglobin and essential hypertension | |
| CN1661062A (en) | Relativity between gene of haptoglobin and essential hypertension | |
| CN1661055A (en) | Relativity between gene of haptoglobin and essential hypertension | |
| CN1661054A (en) | Relativity between gene of haptoglobin and essential hypertension | |
| CN1661058A (en) | Relativity between gene of haptoglobin and essential hypertension | |
| CN1661066A (en) | Relativity between gene of haptoglobin and essential hypertension | |
| CN1661068A (en) | Relativity between gene SNP of insulin receptor and essential hypertension | |
| CN1661060A (en) | Relativity between gene SNP of insulin receptor and essential hypertension | |
| CN1661059A (en) | Relativity between SNP gene of insulin receptor and essential hypertension | |
| CN1661061A (en) | Relativity between SNP gene of insulin receptor and essential hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |